tape icon
Project Size
16,000 SF
calendar icon
Schedule
Apr 2023
tape icon
# Of Employees
160
calendar icon
Cost
Confidential
map location icon
Location
Germantown, MD
video icon
Watch
Testimonial Video
Play Video

Barinthus Biotherapeutics (formerly Vaccitech)

New facility answers acquisition and expansion needs.

A spinout of Oxford University, Barinthus Biotherapeutics (formerly Vaccitech) discovers and develops immunotherapeutic products and vaccines for the treatment and prevention of infectious disease and cancer. In 2021, the company expanded with the acquisition of Avidia Technologies in Maryland. The challenge: With the acquisition and with six clinical candidates ready to advance to trials, the company needed a larger facility for a new office headquarters and R&D facility. The solution: Call on FLGX Owner’s Representation service.

A larger and more effective environment for research
Through Phase I and Phase II Owner's Representation Services, FLGX assisted Barinthus Biotherapeutics (formerly Vaccitech) in the successful transition to a larger 16,000-square-foot facility in Germantown, MD, to serve as the company’s new office headquarters and R&D center with a state-of-the-art wet lab. To achieve an optimum outcome, FLGX was instrumental in strategizing and implementing the timeline and capital investment for the significant and successful expansion.

Nick Fullenkamp photo
"The Facility Logix team immediately brought expertise and credibility to our project. They also are experts in project management and that came across really clear right away... They do these builds all the time and they have a level of experience that most people in our industry do not."

- Nick Fullenkamp, Vice President of Corporate Development, Barinthus Biotherapeutics (formerly Vaccitech)

Barinthus Biotherapeutics (formerly Vaccitech)

New facility answers acquisition and expansion needs.

Project Size: 16,000 SF
Schedule: Apr 2023
# Of Employees: 160
Cost: Confidential
Location: Germantown, MD

A spinout of Oxford University, Barinthus Biotherapeutics (formerly Vaccitech) discovers and develops immunotherapeutic products and vaccines for the treatment and prevention of infectious disease and cancer. In 2021, the company expanded with the acquisition of Avidia Technologies in Maryland. The challenge: With the acquisition and with six clinical candidates ready to advance to trials, the company needed a larger facility for a new office headquarters and R&D facility. The solution: Call on FLGX Owner’s Representation service.

A larger and more effective environment for research
Through Phase I and Phase II Owner's Representation Services, FLGX assisted Barinthus Biotherapeutics (formerly Vaccitech) in the successful transition to a larger 16,000-square-foot facility in Germantown, MD, to serve as the company’s new office headquarters and R&D center with a state-of-the-art wet lab. To achieve an optimum outcome, FLGX was instrumental in strategizing and implementing the timeline and capital investment for the significant and successful expansion.

Nick Fullenkamp photo
"The Facility Logix team immediately brought expertise and credibility to our project. They also are experts in project management and that came across really clear right away... They do these builds all the time and they have a level of experience that most people in our industry do not."

- Nick Fullenkamp, Vice President of Corporate Development, Barinthus Biotherapeutics (formerly Vaccitech)